The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Herpes Zoster & Tofacitinib

Herpes Zoster & Tofacitinib

October 3, 2017 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Shingles, also known as herpes zoster (HZ), is a common and sometimes debilitating disease that disproportionately affects elderly individuals and those who are immunocompromised. Patients with rheumatoid arthritis (RA) have a 1.5–2-fold higher risk of developing HZ compared with healthy adults. Treatment with some disease-modifying anti-rheumatic drugs (DMARDs) has been shown to increase this risk. Tofacitinib has been shown to increase the risk of developing HZ, particularly when it is given in combination with methotrexate or prednisone.

You Might Also Like
  • Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib
  • Herpes Zoster & the Risk of Stroke in Patients with Autoimmune Diseases
  • 2015 ACR/ARHP Annual Meeting: Stroke Risk Elevated after Herpes Zoster Infection Among Patients with Autoimmune Disease

Thus, vaccination is recommended for patients ages 50 years and older, prior to starting treatment with biologic agents or tofacitinib. Two studies in this issue of Arthritis & Rheumatology tackle the topic of live zoster vaccination in patients with rheumatoid arthritis before starting and concomitant with tofacitinib.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Study 1
The first, “The Safety and Immunogenicity of Live Zoster Vaccination in Patients with Rheumatoid Arthritis Before Starting Tofacitinib,” evaluated the effect of tofacitinib, an oral JAK inhibitor used for the treatment of RA, on the immune response to and safety of live zoster vaccine (LZV).1

In this phase II, 14-week, placebo-controlled trial, patients ages 50 years and older who had active RA and were receiving background methotrexate were given LZV and randomized to receive tofacitinib 5 mg twice daily or placebo two to three weeks postvaccination. The researchers measured humoral responses (the varicella zoster virus [VZV]–specific IgG level as determined by glycoprotein enzyme-linked immunosorbent assay) and cell-mediated responses (VZV-specific T cell enumeration, as determined by enzyme-linked immunospot assay) at baseline and two weeks, six weeks and 14 weeks postvaccination. End points included the geometric mean fold rise (GMFR) in VZV-specific IgG levels (primary end point) and T cells (spot-forming cells/106 peripheral blood mononuclear cells) at six weeks postvaccination.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: One hundred twelve patients were randomized to receive tofacitinib (n=55) or placebo (n=57). Six weeks postvaccination, the GMFR in VZV-specific IgG levels was 2.11 in the tofacitinib group and 1.74 in the placebo group, and the VZV-specific T cell GMFR was similar in the tofacitinib group and the placebo group (1.50 and 1.29, respectively). Serious adverse events occurred in three patients in the tofacitinib group (5.5%) and 0 patients (0.0%) in the placebo group. One patient who lacked preexisting VZV immunity developed a disseminated rash on day 16 postvaccination (two days after starting tofacitinib). This resolved after tofacitinib was discontinued and the patient received antiviral treatment.

Study 2
The second study, “Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy,” evaluated whether concomitant treatment with conventional synthetic DMARDs (csDMARDs) or glucocorticoids (GCs) contributes to the increased risk of HZ in RA patients treated with tofacitinib.2

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: herpes zoster, Tofacitinib

You Might Also Like:
  • Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib
  • Herpes Zoster & the Risk of Stroke in Patients with Autoimmune Diseases
  • 2015 ACR/ARHP Annual Meeting: Stroke Risk Elevated after Herpes Zoster Infection Among Patients with Autoimmune Disease
  • Tofacitinib Decreases Inflammation in Early RA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)